Cited by 125Functional Brain Connectivity StudiesTreatment of Major DepressionTranscranial Magnetic Stimulation Studies

Effect of intrinsic patterns of functional brain connectivity in moderating antidepressant treatment response in major depression

Open access
Chin Fatt, Cherise R., Jha, Manish K., Cooper, Crystal M., Fonzo, Gregory, South, Charles, Grannemann, Bruce, Carmody, Thomas, Greer, Tracy L. +10 more·2020·American Journal of Psychiatry

Abstract

OBJECTIVE: Major depressive disorder is associated with aberrant resting-state functional connectivity across multiple brain networks supporting emotion processing, executive function, and reward processing. The purpose of this study was to determine whether patterns of resting-state connectivity between brain regions predict differential outcome to antidepressant medication (sertraline) compared with placebo. METHODS: Participants in the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) study underwent structural and resting-state functional MRI at baseline. Participants were then randomly assigned to receive either sertraline or placebo treatment for 8 weeks (N=279). A region of interest-based approach was utilized to compute functional connectivity between brain regions. Linear mixed-model intent-to-treat analyses were used to identify brain regions that moderated (i.e., differentially predicted) outcomes between the sertraline and placebo arms. RESULTS: Prediction of response to sertraline involved several within- and between-network connectivity patterns. In general, higher connectivity within the default mode network predicted better outcomes specifically for sertraline, as did greater between-network connectivity of the default mode and executive control networks. In contrast, both placebo and sertraline outcomes were predicted (in opposite directions) by between-network hippocampal connectivity. CONCLUSIONS: This study identified specific functional network-based moderators of treatment outcome involving brain networks known to be affected by major depression. Specifically, functional connectivity patterns of brain regions between and within networks appear to play an important role in identifying a favorable response for a drug treatment for major depressive disorder.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.2019.18070870

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Studies of late-life depression showed increased FCS in the inferior parietal lobule and parahippocampal gyrus and decreased FCS in the somatosensory and motor cortices compared to HCs.

    “Similar to the alteration patterns in our results, studies of late-life depression showed increased FCS in the inferior parietal lobule and parahippocampal gyrus and decreased FCS in the somatosensory and motor cortices compared to HCs [69].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Veer IM, Beckmann CF, van Tol M-J, et al: Whole brain resting-state analysis reveals decreased functional connectivity in major de- pression. Front Syst Neurosci, September 20, 2010; 4(41):1-10
  2. First MB, Spitzer RL, Gibbon M, et al: Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, New York State Psychiatric Institute, Bio- metric Research, 2002

Cited by

Sorted by citations

Authors
Chin Fatt, C. R., Jha, M. K., Cooper, C. M., Fonzo, G., South, C., Grannemann, B., Carmody, T., Greer, T. L., Kurian, B., Fava, M., McGrath, P. J., Adams, P., McInnis, M., Parsey, R. V., Weissman, M., Phillips, M. L., Etkin, A., & Trivedi, M. H.
Affiliations
  • Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas (Chin Fatt, Jha, Cooper, South, Grannemann, Carmody, Greer, Kurian, Trivedi); Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York (Jha); Department of Psychiatry and Behavioral Sciences and Stanford Neurosciences Institute, Stanford University, Stanford, Calif. (Fonzo, Etkin); Mental Illness Research, Education, and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, Calif. ...
  • VA Palo Alto Health Care System (US)
Venue
American Journal of Psychiatry
Published
2020-02-01
Volume
177
Issue
2
Pages
143-154
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2973556437
Cited by
125
References
49
Citations by year
2026: 11 · 2025: 16 · 2024: 24 · 2023: 16 · 2022: 24 · 2021: 15 · 2020: 16 · 2019: 3
FWCI
8.43
Type
journal article
Language
en
Open access
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • U.S. Department of Veterans Affairs
  • Abbott Laboratories
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Massachusetts General Hospital
  • Biogen
  • CeNeRx
  • Pharmavite
  • University of Pittsburgh
  • Sunovion
  • National Alliance for Research on Schizophrenia and Depression
  • Vanda Pharmaceuticals
  • Jazz Pharmaceuticals
  • Hersh Foundation
  • Amarin Corporation
  • ACADIA Pharmaceuticals
  • Orexigen Therapeutics
  • Avanir Pharmaceuticals
  • Cerecor
  • Supernus Pharmaceuticals
  • American Society of Clinical Psychopharmacology
  • FORUM Pharmaceuticals
  • Belvoir Media Group
  • Vistagen Therapeutics
  • Dainippon Sumitomo Pharma
  • Eisai
  • Servier
  • H. Lundbeck A/S
  • Stony Brook University
  • Allergan
  • Amarin Pharma
  • Takeda Pharmaceuticals International
  • National Institute of Mental Health (U01MH092250, U01MH092221)
  • National Institute on Drug Abuse
  • National Center for Complementary and Alternative Medicine
  • NIH Clinical Center
  • Janssen Research and Development
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Functional Brain Connectivity Studies
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
Keywords
major depressive disorder, resting-state functional connectivity, antidepressant response, sertraline, placebo response, default mode network, frontoparietal network, hippocampal connectivity, treatment moderators, treatment outcome prediction
MeSH terms
Adolescent, Adult, Aged, Antidepressive Agents, Brain, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Neural Pathways, Predictive Value of Tests, Treatment Outcome, Sertraline, Young Adult, Functional Neuroimaging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review